September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Oral kalliginogenase improved chorioretinal blood flow levels and significantly reduced subfoveal choroidal thickness in diabetic macular edema patients.
Author Affiliations & Notes
  • Eiko Tsuiki
    Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University , NAGASAKI, Japan
  • Kiyoshi Suzuma
    Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University , NAGASAKI, Japan
    Ophthalmology and Visual Sciences, Kyoto University, KYOTO, Japan
  • Yasser Helmy Mohamed
    Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University , NAGASAKI, Japan
  • Yoshihisa Yamada
    Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University , NAGASAKI, Japan
  • MAKIKO MATSUMOTO
    Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University , NAGASAKI, Japan
  • Takashi Kitaoka
    Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University , NAGASAKI, Japan
  • Footnotes
    Commercial Relationships   Eiko Tsuiki, None; Kiyoshi Suzuma, None; Yasser Mohamed, None; Yoshihisa Yamada, None; MAKIKO MATSUMOTO, None; Takashi Kitaoka, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3260. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Eiko Tsuiki, Kiyoshi Suzuma, Yasser Helmy Mohamed, Yoshihisa Yamada, MAKIKO MATSUMOTO, Takashi Kitaoka; Oral kalliginogenase improved chorioretinal blood flow levels and significantly reduced subfoveal choroidal thickness in diabetic macular edema patients.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3260.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We investigated the effect of oral kallidinogenase on chorioretinal blood flow and subfoveal choroidal thickness (SCT) in diabetic macular edema (DME) patients who underwent focal laser and sub-Tenon injection of triamcinolone acetonide for clinically significant macular edema.

Methods : In this prospective, randomized clinical study (UMIN000005339), best corrected visual acuity (BCVA), SCT and chorioretinal blood flow level were measured in 21 patients (22 eyes) at the Department of Ophthalmology & Visual Sciences, Nagasaki University. Chorioretinal blood flow levels at the macula were measured by LSFG-NAVITM (Softcare, Fukuoka, Japan) and evaluated using the mean blur rate (MBR). These were measured at baseline and at 1, 3, and 6 months after treatment initiation.

Results : Twelve eyes were assigned to a kallidinogenase-treated group and 10 eyes were assigned to an untreated group. Compared to baseline (100%), MBR at the macula of 6 months after treatment significantly decreased to 86.2±17.2 % in untreated group (P<0.05), though it has maintained 100.7±15.2% in patients in kallidinogenase-treated group. The mean SCT at baseline was 298.1±75.0 μm (with kalliginogenase) and 292.1±101.6 μm (without kalliginogenase), there was no significant difference between two groups. The mean SCT after treatment in kalliginogenase-treated group was 269.8±68.1μm (1 month), 283.7±75.7μm (3 months) and 287.1±75.3μm (6 months) respectively, which was significantly thinner than that before treatment (P<0.01). BCVA at 6 months after treatment significantly improved in kallidinogenase-treated group (P<0.05). Both of SCT and BCVA exhibited no statistically significant difference during 6 months after treatment in untreated group.

Conclusions : Kallidinogenase is able to improve chorioretinal blood flow levels and significantly reduced SCT in DME patients.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×